Moderne antidepressive Therapie

 

 Buy Article Permissions and Reprints

Zusammenfassung

Anliegen Literaturübersicht aktueller pharmakologischer Behandlungsempfehlungen und evidenzbasierter Leitlinien in der Akutbehandlung der schweren depressiven Episode. Methode Systematische Auswertung aktueller peer-reviewed Übersichtsarbeiten, Metaanalysen und Behandlungsleitlinien im Hinblick auf evidenzbasierte Schlussfolgerungen für die konkrete psychiatrische Praxis. Ergebnisse Im Gegensatz zur Wirksamkeit, die bei den Antidepressiva im Wesentlichen ähnlich ist, herrschen bezüglich der Verträglichkeit zum Teil große Unterschiede, die den Einsatz im psychiatrischen Alltag maßgeblich bestimmen. Für den Fall einer häufig vorkommenden Therapieresistenz existieren gut untersuchte Algorithmen für eine optimale Weiterbehandlung. Schlussfolgerungen Die Vielzahl wirksamer antidepressiver Verfahren lässt eine individuelle und patientengerechte Behandlung zu. Eine Orientierung an festgelegten Stufenplänen sichert das optimale Ausschöpfen dieser Möglichkeiten.

Abstract

Objective A systematic review on empirical results of current guidelines and recommendations with focus on efficacy and tolerability of antidepressant pharmacological treatment options. Methods A critical, systematic evaluation of peer reviewed surveys, meta-analyses and guidelines is provided with the focus on evidence based consequences for the psychiatric clinical practice in the treatment of major depressive episodes. Results Most of modern and classic antidepressants have not proved differences in studies regarding comparative effectiveness. In contrast clinical decisions are increasingly guided by differences of tolerability, which are clearly documented in the current literature. Many algorithm based treatment options exist to face the common problem of treatment resistance. Conclusions The multitude of effective antidepressant options provides an individual and patient orientated treatment. To achieve an optimal utilization of these options, an orientation on multi-step treatment plans is useful.

Literatur

• 1 Bauer M, Whybrow P C, Angst J, Versiani M, Moller H J. World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.  World J Biol Psychiatry. 2002;  3 (1) 5-43
  CrossrefPubMedGoogle Scholar
• 2 Bauer M, Bschor T, Pfennig A, Whybrow P C, Angst J, Versiani M, Moller H J, Disorders D T. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.  World J Biol Psychiatry. 2007;  8 (2) 67-104
  CrossrefPubMedGoogle Scholar
• 3 de Jonghe F, Kool S, van Aalst G. et al . Combining psychotherapy and antidepressants in the treatment of depression.  J Affect Disord. 2001;  64 217-229
  CrossrefPubMedGoogle Scholar
• 4 Paykel E S, Scott J, Teasdale J D. et al . Prevention of relapse in residual depression by cognitive therapy: A controlled trial.  Arch Gen Psychiatry. 1999;  56 (9) 829-835
  PubMedGoogle Scholar
• 5 Anderson I M, Nutt D J, Deakin J F. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.  J Psychopharmacol. 2000;  14 3-20
  CrossrefPubMedGoogle Scholar
• 6 Möller H J, Fuger J, Kasper S. Efficacy of new generation antidepressants: meta-analysis of imipramine-controlled studies.  Pharmacopsychiatry. 1994;  27 215-223
  PubMedGoogle Scholar
• 7 American Psychiatric Association . Practice guideline for the treatment of patients with major depressive disorder (revision).  Am J Psychiatry. 2000;  157 1-45
  PubMedGoogle Scholar
• 8 Bech P, Cialdella P, Haugh M C, Birkett M A, Hours A, Boissel J P, Tollefson G D. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression.  Br J Psychiatry. 2000;  176 421-428
  CrossrefPubMedGoogle Scholar
• 9 Geddes J R, Freemantle N, Mason J, Eccles M P, Boynton J. Selective serotonin reuptake inhibitors (SSRIs) for depression (Cochrane Review). Update Software. Oxford; The Cochrane Library 2001 3
  Google Scholar
• 10 Danish University Antidepressant Group . Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study.  Psychopharmacology (Berl). 1986;  90 131-138
  PubMedGoogle Scholar
• 11 Anderson I M. Meta-analytical studies on new antidepressants.  Br Med Bull. 2001;  57 161-178
  CrossrefPubMedGoogle Scholar
• 12 Einarson T R, Arikian S R, Casciano J, Doyle J J. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.  Clin Ther. 1999;  21 296-308
  CrossrefPubMedGoogle Scholar
• 13 Stahl S M, Entsuah R, Rudolph R L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.  Biol Psychiatry. 2002;  52 1166-1174
  CrossrefPubMedGoogle Scholar
• 14 Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2005 4
  Google Scholar
• 15 Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.  J Clin Psychopharmacol. 2006;  26 (2) 121-127
  CrossrefPubMedGoogle Scholar
• 16 Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression.  Expert Opin Pharmacother. 2000;  1 917-933
  CrossrefPubMedGoogle Scholar
• 17 Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors.  Acta Psychiatr Scand. 2000;  403 17-25
  PubMedGoogle Scholar
• 18 AHCPR (Agency for Health Care Policy and Research) .Evidence Report on Treatment of Depression: Newer Pharmacotherapies. San Antonio Evidence-Based Practice Center. Washington, DC; AHCPR, Evidence-Based Practice Centers. AHCPR pub 1999 No. 99-E014
  Google Scholar
• 19 Angst J, Stassen H H. Methodische Aspekte von Studien zur antidepressiven Wirksamkeit. Spezielle Aspekte der antidepressiven Therapie. Neuere Ergebnisse zu Moclobemid. München; MMV Medizin Verlag GmbH 1999: 147-166
  Google Scholar
• 20 Beck A T, Ward C H, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression.  Arch Gen Psychiatry. 1961;  4 561-571
  CrossrefPubMedGoogle Scholar
• 21 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;  23 56-62
  CrossrefPubMedGoogle Scholar
• 22 Stassen H H, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses.  Pharmacopsychiatry. 1996;  29 87-96
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Thase M E, Rush A J. Treatment-resistant depression. In Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. New York; Raven Press 1995: 1081-1097
  Google Scholar
• 24 Nelson J C. Managing treatment-resistant depression.  J Clin Psychiatry. 2003;  64 (suppl 1) 5-12
  CrossrefPubMedGoogle Scholar
• 25 Nolen W A, Zohar J, Roose S P, Amsterdam J D. Refractory Depression: Current Strategies and Future Directions. Chichester; J. Wiley & Sons 1994
  Google Scholar
• 26 Marangell L B. Switching antidepressants for treatment-resistant major depression.  J Clin Psychiatry. 2001;  62 (Suppl 18) 12-17
  PubMedGoogle Scholar
• 27 Ruhe H G, Huyser J, Swinkels J A, Schene A H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.  J Clin Psychiatry. 2006;  67 (12) 1836-1855
  CrossrefPubMedGoogle Scholar
• 28 Reynaert-Dupuis C, Zdanowicz N, Leyman S, Mignon A, Seghers S. for 600A-GAP-BE Study Group . Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment.  Primary Care Psychiatry. 2002;  8 63-68
  CrossrefPubMedGoogle Scholar
• 29 Thase M E, Rush A J, Howland R H, Kornstein S G, Kocsis J H, Gelenberg A J, Schatzberg A F, Koran L M, Keller M B, Russell J M, Hirschfeld R M, LaVange L M, Klein D N, Fawcett J, Harrison W. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.  Arch Gen Psychiatry. 2002;  59 233-239
  CrossrefPubMedGoogle Scholar
• 30 Fava M, McGrath P J, Sheu W P. Reboxetine Study Group . Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.  J Clin Psychopharmacol. 2003;  23 365-369
  CrossrefPubMedGoogle Scholar
• 31 Thase M E, Rush A J. When at first you don't succeed: sequential strategies for antidepressant nonresponders.  J Clin Psychiatry. 1997;  58 (suppl 13) 23-29
  PubMedGoogle Scholar
• 32 De Battista C, Solvason H B, Poirier J, Kendrick E, Schatzberg A F. A prospective trail of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.  J Clin Psychopharmacol. 2003;  23 27-30
  CrossrefPubMedGoogle Scholar
• 33 Licht R W, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomized study of extended duration of treatment, dose increase or mianserin augmentation.  Psychopharmacology. 2002;  161 143-151
  CrossrefPubMedGoogle Scholar
• 34 Trivedi M H, Fava M, Wisniewski S R, Thase M E, Quitkin F, Warden D, Ritz L, Nierenberg A A, Lebowitz B D, Biggs M M, Luther J F, Shores-Wilson K, Rush A J. Medication augmentation after the failure of SSRIs for depression.  N Engl J Med. 2006;  354 (12) 1243-1252
  CrossrefPubMedGoogle Scholar
• 35 Rush A J, Fava M, Wisniewski S R, Lavori P W, Trivedi M H, Sackeim H A, Thase M E, Nierenberg A A, Quitkin F M, Kashner T M, Kupfer D J, Rosenbaum J F, Alpert J, Stewart J W, McGrath P J, Biggs M M, Shores-Wilson K, Lebowitz B D, Ritz L, Niederehe G. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.  Control Clin Trials. 2004;  25 (1) 119-142
  PubMedGoogle Scholar
• 36 Bauer M, Crossley N A, Gerber S, Bschor T. The acute antidepressive effects of lithium: from monotherapy to augmentation. In: Bauer M, Grof P, Müller-Oerlinghausen (eds) Lithium in Neuropsychiatry - The Comprehensive Guide. Abingdon; Informa Healthcare 2006: 109-128
  Google Scholar
• 37 Katona C L, Abou-Saleh M T, Harrison D A, Nairac B A, Edwards D RL, Lock T, Burns R A, Robertson M M. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.  Br J Psychiatry. 1995;  166 80-86
  CrossrefPubMedGoogle Scholar
• 38 Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors.  Pharmacopsychiatry. 2001;  34 119-127
  Article in Thieme ConnectPubMedGoogle Scholar
• 39 Joffe R T, Singer W, Levitt A J, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.  Arch Gen Psychiatry. 1993;  50 387-393
  CrossrefPubMedGoogle Scholar
• 40 Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression - A meta-analysis of placebo-controlled studies.  J Clin Psychopharmacol. 1999;  19 427-434
  CrossrefPubMedGoogle Scholar
• 41 Ostroff R, Nelson J C. Risperidone augmentation of SSRIs in major depression.  J Clin Psychiatry. 1999;  60 256-259
  CrossrefPubMedGoogle Scholar
• 42 Barbee J G, Conrad E J, Jamhour N J. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.  J Clin Psychiatry. 2004;  65 975-981
  CrossrefPubMedGoogle Scholar
• 43 Bauer M, Whybrow P C. Thyroid hormone, neural tissue and mood modulation.  World J Biol Psychiatry. 2001;  2 57-67
  PubMedGoogle Scholar
• 44 Altshuler L L, Bauer M, Frye M A, Gitlin M J, Mintz J, Szuba M P, Leight K L, Whybrow P C. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature.  Am J Psychiatry. 2001;  158 1617-1622
  CrossrefPubMedGoogle Scholar
• 45 Bauer M, Hellweg R, Gräf K J, Baumgartner A. Treatment of refractory depression with high-dose thyroxine.  Neuropsychopharmacology. 1998;  18 444-455
  CrossrefPubMedGoogle Scholar
• 46 Bauer M, Baur H, Berghöfer A, Ströhle A, Hellweg R, Müller-Oerlinghausen B, Baumgartner A. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders.  J Affect Disord. 2002;  68 285-294
  CrossrefPubMedGoogle Scholar
• 47 Adli M, Bauer M, Rush A J. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review.  Biol Psychiatry. 2006;  59 (11) 1029-1038
  CrossrefPubMedGoogle Scholar
• 48 Rech R, Könlein O, Schmauß M, Messer T. Untersuchung zur Auswirkung konventioneller versus moderner Antidepressiva auf den Krankheitsverlauf depressiver Patienten.  Psychiat Prax. 2007;  34, Supplement 1 S100-S102
  Article in Thieme ConnectPubMedGoogle Scholar
• 49 Hausmann A, Walpoth M, Conca A. Sind Antidepressiva in der Behandlung der bipolaren Depressionen obsolet?.  Neuropsychiatrie. 2005;  19 45-51
  PubMedGoogle Scholar
• 50 Safer D J, Zito J M. Do antidepressants reduce suicide rates?.  Public Health. 2007;  121 (4) 274-277
  CrossrefPubMedGoogle Scholar
• 51 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review.  BMJ. 2005;  330 (7488) 385
  CrossrefPubMedGoogle Scholar
• 52 Jick H, Kaye J A, Jick S S. Antidepressants and the rick of suicidal behaviors.  JAMA. 2004;  292 (3) 338-343
  CrossrefPubMedGoogle Scholar
• 53 Teicher M H, Glod C A, Cole J O. Antidepressant drugs and the emergence of suicidal tendencies.  Drug Saf. 1993;  8 (3) 186-212
  CrossrefPubMedGoogle Scholar
• 54 Hegerl U. Antidepressants and suicidality: Risk - benefit analysis.  Nervenarzt. 2007;  78 (1) 7-14
  Google Scholar

Prof. Dr. Dr. Michael Bauer

Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden

Fetscherstraße 74

01307 Dresden

Email: michael.bauer@uniklinikum-dresden.de